Online inquiry

IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5840MR)

This product GTTS-WQ5840MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Psoriasis, Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5840MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13758MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ1838MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ14825MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ256MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ14572MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ4942MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ5082MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ9159MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW